openPR Logo

Press Releases from BioFocus (7 total)

Argenta and BioFocus announce two-year extension of drug discovery collaboration …

Galapagos NV (Euronext: GLPG) announced today that its service division Argenta has extended its integrated contract drug discovery agreement with Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY). Total potential value of the contract extension is up to £21.5 million (€23.4 million). This is the third such extension since the agreement was announced in December 2005. The agreement covers a number of drug discovery

BioFocus and InterMed Discovery announce Marketing Collaboration

BioFocus, an integrated drug discovery service partner, and InterMed Discovery GmbH (IMD), a natural product lead-discovery company, today announced a marketing collaboration to offer enhanced natural product discovery to the pharmaceutical, animal health, and agrochemical industries. No financial details were disclosed. Under the terms of the collaboration, IMD will make its natural product screening libraries available and provide follow-on services to BioFocus. BioFocus will then incorporate these as part of

BioFocus enters collaboration with Michael J. Fox Foundation

BioFocus announced today that it has signed a collaboration agreement with The Michael J. Fox Foundation for Parkinson’s Research, a not-for-profit organization focused on developing therapies for Parkinson’s disease. Under the agreement, BioFocus will perform fragment-based screening, assay development and hit-finding programs, to identify compounds that have the basis for a novel Parkinson’s disease diagnostic test. “We are delighted to have the opportunity to support The Michael J.

BioFocus extends collaboration with Usher III Initiative

BioFocus announced today that it has expanded a collaboration with the Usher III Initiative, Inc., a non-profit organization focused on developing treatments for Usher syndrome type III, a rare genetic disorder that causes the loss of hearing and vision. BioFocus and the Usher III Initiative began their collaboration in July 2010 with BioFocus performing an integrated drug discovery program encompassing medicinal chemistry, ADME and biological sciences, aiming at a

Astellas Pharma and BioFocus sign target discovery agreement

BioFocus announced today that it has signed a collaboration agreement with Astellas Pharma Inc. focused on discovering novel targets in the field of CNS disorders. Under the agreement, BioFocus will utilize its SilenceSelect® target discovery platform to deliver validated targets to enhance the Astellas neurology pipeline and will receive research funding and success payments based on the progress of the collaboration. “We are delighted to support Astellas Pharma

BioFocus and Almac collaborate to offer fluorescent lifetime assays

BioFocus announced today that it has entered into collaboration with Almac allowing BioFocus customers with compound screening and profiling requirements to access Almac’s FLEXYTETM fluorescence lifetime (FLT) assays. Integrating the assay technology allows BioFocus to offer an FLT platform that will complement its current target class capabilities, provide access to previously inaccessible epigenetic targets and offer alternative approaches to fragment-based screens and kinetic profiling. “Being able to incorporate FLT assays in

University of Nottingham and BioFocus sign compound management agreement

BioFocus announced today that its Compound Focus, Inc. subsidiary has signed a compound management services agreement with the University of Nottingham, UK. Under the terms of this agreement, Compound Focus will select, source, acquire, perform quality control checks and reformat a compound collection before returning to the Managed Chemical Compound Collection (MCCC) at the University of Nottingham. These services will be provided by Compound Focus’ compound management facility

Go To Page:   1 2 3 4 5 6 7 8 9 10